Evidence map›Paper›PMID 30648127›Full record

ArticleOpen forum infectious diseases2019

Antibody Responses in HIV-Infected Patients With Advanced Immunosuppression and Asymptomatic Cryptococcal Antigenemia.

Admire Hlupeni, Antonio Nakouzi, Tao Wang, Kathryn F Boyd, Tariro A Makadzange, Chiratidzo E Ndhlovu, Liise-Anne Pirofski

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Effects of human immunoglobulin A onMicrobiology spectrum · 2025
    Article
  4. Review
  5. Article
  6. Association of Antibody Immunity With Cryptococcal Antigenemia and Mortality in a South African Cohort With Advanced Human Immunodeficiency Virus Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  7. Open forum infectious diseases · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Antibody immunity and natural resistance to cryptococcosis.Current tropical medicine reports · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Admire HlupeniDepartment of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Antonio NakouziDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
Tao WangDepartment of Epidemiology and Biostatistics, Albert Einstein College of Medicine, Bronx, New York.
Kathryn F BoydDepartment of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Tariro A MakadzangeDepartment of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Chiratidzo E NdhlovuDepartment of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Liise-Anne PirofskiDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
University of Zimbabwe · ZWAlbert Einstein College of Medicine · USMontefiore Medical Center · US

Funding

B cell subsets and immunity to cryptococcosisR01AI097096 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PIROFSKI, LIISE-ANNE · 2012 to 2016
$2.7M
Determinants of Immune Control in HIV perinatally infected children in sub-SaharaK08AI104348 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MAKADZANGE, AZURE TARIRO · 2013 to 2016
$745k
CGH CDC HHS U01 GH000737NIAID NIH HHS K08 AI104348NIAID NIH HHS R01 AI097096
6 · The paper itself

Abstract

backgroundThere are no host biomarkers of risk for HIV-associated cryptococcal meningitis (CM) except CD4+ T-cell deficiency. At present, serum cryptococcal antigen (CrAg) screening of those with CD4 <100 cells/µL is used to identify persons at risk for HIV-associated CM. We determined if plasma antibody profiles could discriminate CrAg+ from CrAg- patients.

methodsWe performed serological analyses of 237 HIV-infected asymptomatic Zimbabwean patients with CD4 <100 cells/µL; 125 CrAg- and CrAg+ but cerebrospinal fluid CrAg- by CrAg lateral flow assay. We measured plasma immunoglobulin M (IgM), immunoglobulin G (IgG) 1, and IgG2 concentrations by Luminex, and titers of

resultsGXM-IgG, -IgM, and -IgG2 levels were significantly higher in CrAg+ patients, whereas natural Lam-IgM and Lam-IgG were higher in CrAg- patients before and after adjustment for age, sex, and CD4 T-cell count, despite overlap of values. To address this variability and better discriminate the groups, we used Akaike Information Criteria to select variables that independently predicted CrAg+ status and included them in a receiver operating characteristic curve to predict CrAg status. By inclusion of CD4, GXM-IgG, GXM-IgM, and Lam-IgG, -IgG2, and -IgM, this model had an 80.4% probability (95% confidence interval, 0.75-0.86) of predicting CrAg+ status.

conclusionsStatistical models that include multiple serological variables may improve the identification of patients at risk for CM and inform new directions in research on the complex role that antibodies may play in resistance and susceptibility to CM.

Indexed as

antibodycryptococccal antigenenmiaglucuronoxylomannanHIVIgGIgMimmunoglobulinLaminarinSub-Saharan AfricaZimbabwe

Identifiers

PMID30648127
PMCPMC6329905
OpenAlexW2903902890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.